Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
IS05 - Industry Symposium Sponsored by MSD: Redefining Survival Expectations in Lung Cancer
- 14:15 - 15:15
- 1/28/2021
- Location: Industry Symposia Auditorium (via Industry Hub)
- Not for CME Credit
- Type: Industry Symposium
- Track:
-
+
IS05.03 - Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Lung Cancer
14:30 - 14:45 | Presenter: Roy S. Herbst
- Abstract
No abstract available for this presentation
-
+
IS05.05 - Q&A and Closing Remarks
15:00 - 15:15 | Presenter: Rina Hui, Roy S. Herbst, Corey J. Langer
- Abstract
No abstract available for this presentation
-
+
FP13 - Immunotherapy (Phase II/III Trials)
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Type: Posters (Featured)
- Track: Immunotherapy (Phase II/III Trials)
-
+
FP13.01 - 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in Previously Treated, PD-L1–Positive Advanced NSCLC
00:00 - 00:00 | Presenter: Roy S. Herbst
- Abstract
Loading... -
+
FP13.03 - IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1–Selected NSCLC
00:00 - 00:00 | Presenter: Roy S. Herbst
- Abstract
Loading...
-
+
P01 - Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
-
+
P01.21 - ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era
00:00 - 00:00 | Presenter: Jordi Remon
- Abstract
Loading...
-
+
P09 - Health Services Research/Health Economics - Real World Outcomes
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Health Services Research/Health Economics
-
+
P09.55 - A Platform to Prospectively Link Real-World Clinico-Genomic, Imaging, and Outcomes Data for Patients With Lung Cancer
00:00 - 00:00 | Presenter: Guneet Walia
- Abstract
Loading...
-
+
OA01 - Established Drugs in Special Populations and New Drugs in Established Populations
- 09:15 - 10:15
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Immunotherapy (Phase II/III Trials)
-
+
OA01.04 - Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A
09:25 - 09:35 | Presenter: Fred R Hirsch
- Abstract
Loading...
-
+
ES02 - Pro-Con: Do We Need Biomarkers to Guide the Choice of Immunotherapy Treatment?
- 10:30 - 11:30
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Educational Session
- Track: Immunotherapy (Phase II/III Trials)
-
+
ES02.03 - We Should Use IO Alone as Maintenance
11:00 - 11:15 | Presenter: Roy S. Herbst
- Abstract
No abstract available for this presentation
-
+
OA06 - Updates on EGFR Targeted Perioperative Therapy and Precision Adjuvant Chemotherapy
- 16:45 - 17:45
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Early Stage/Localized Disease
-
+
OA06.03 - Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC
16:45 - 16:55 | Presenter: Margarita Majem
- Abstract
Loading... -
+
OA06.04 - Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLC
16:55 - 17:05 | Presenter: Yi-long Wu
- Abstract
Loading...
-
+
MA08 - Advances in Biomarkers for Immune Checkpoint Blockade and Targeted Therapy in Non Small Cell Lung Carcinoma
- 16:45 - 17:45
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
-
+
MA08.10 - LUNGMAP Master Protocol (LUNGMAP): Concordance Between Plasma ctDNA and Tissue Molecular Analysis
17:20 - 17:25 | Presenter: Philip Christopher Mack
- Abstract
Loading...
-
+
MA11 - Expanding Targetable Genetic Alterations in NSCLC
- 14:15 - 15:15
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Targeted Therapy - Clinically Focused
-
+
MA11.10 - Lung Master Protocol (Lung-MAP) Next Generation Sequencing Analysis of Advanced Squamous Cell Cancers (SWOG S1400)
14:50 - 14:55 | Presenter: David Kozono
- Abstract
Loading...
